192 related articles for article (PubMed ID: 27983725)
1. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.
Botta C; Di Martino MT; Ciliberto D; Cucè M; Correale P; Rossi M; Tagliaferri P; Tassone P
Blood Cancer J; 2016 Dec; 6(12):e511. PubMed ID: 27983725
[TBL] [Abstract][Full Text] [Related]
2. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S
Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890
[TBL] [Abstract][Full Text] [Related]
3. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
Khan R; Dhodapkar M; Rosenthal A; Heuck C; Papanikolaou X; Qu P; van Rhee F; Zangari M; Jethava Y; Epstein J; Yaccoby S; Hoering A; Crowley J; Petty N; Bailey C; Morgan G; Barlogie B
Haematologica; 2015 Sep; 100(9):1214-21. PubMed ID: 26022710
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
6. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.
Schinke C; Qu P; Mehdi SJ; Hoering A; Epstein J; Johnson SK; van Rhee F; Zangari M; Thanendrarajan S; Barlogie B; Davies FE; Yaccoby S; Morgan GJ
Clin Cancer Res; 2018 Jun; 24(12):2913-2919. PubMed ID: 29563136
[No Abstract] [Full Text] [Related]
7. Differential Expression of Non-Shelterin Genes Associated with High Telomerase Levels and Telomere Shortening in Plasma Cell Disorders.
Panero J; Stella F; Schutz N; Fantl DB; Slavutsky I
PLoS One; 2015; 10(9):e0137972. PubMed ID: 26366868
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
9. Low-risk identification in multiple myeloma using a new 14-gene model.
Chen T; Berno T; Zangari M
Eur J Haematol; 2012 Jul; 89(1):28-36. PubMed ID: 22620863
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow expression of CCL3 is not correlated with the extent of lytic bone lesions.
Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A
Acta Haematol; 2014; 132(2):129-33. PubMed ID: 24556596
[No Abstract] [Full Text] [Related]
11. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
Chim CS; Liang R; Leung MH; Kwong YL
J Clin Pathol; 2007 Jan; 60(1):104-6. PubMed ID: 17213358
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR
J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312
[TBL] [Abstract][Full Text] [Related]
14. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
Fagerli UM; Holt RU; Holien T; Vaatsveen TK; Zhan F; Egeberg KW; Barlogie B; Waage A; Aarset H; Dai HY; Shaughnessy JD; Sundan A; Børset M
Blood; 2008 Jan; 111(2):806-15. PubMed ID: 17934070
[TBL] [Abstract][Full Text] [Related]
15. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
16. Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.
Palma BD; Guasco D; Pedrazzoni M; Bolzoni M; Accardi F; Costa F; Sammarelli G; Craviotto L; De Filippo M; Ruffini L; Omedè P; Ria R; Aversa F; Giuliani N
Leukemia; 2016 Feb; 30(2):409-16. PubMed ID: 26419509
[TBL] [Abstract][Full Text] [Related]
17. MMSA-1 expression pattern in multiple myeloma and its clinical significance.
Meng S; Lu C; Zhang W; Shen W; Wei Y; Su D; Zhou F
Clin Exp Med; 2016 Nov; 16(4):599-609. PubMed ID: 26493349
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
[TBL] [Abstract][Full Text] [Related]
19. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).
Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H
Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
